At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
06998 EDDING GENOR
Market Closed 05-22 16:08:22
2.110
-0.020
-0.94%
High2.180
Low2.100
Vol1.12M
Open2.160
D1 Closing2.130
Amplitude3.76%
Mkt Cap4.19B
Tradable Cap4.19B
Total Shares1.99B
T/O2.41M
T/O Rate0.06%
Tradable Shares1.99B
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
EDDING GENOR Appoints Wang Qianhui as Joint Company Secretary
Hong Kong Stock Announcement Highlights | SSY GROUP Reports Q1 Profit Attributable to Shareholders of Approximately HK$171 Million, Up 1.6% Year-on-Year
Edding Genor Group Holdings Ltd, formerly Genor Biopharma Holdings Ltd, is a company primarily engaged in the biopharmaceuticals business. The Company’s main business is engaged in the discovery, development and commercialization of biopharmaceutical products for human use. The Company’s product pipelines include Lerociclib (GB491), GB261, GB263T, Infliximab (GB242), Coprelotamab (GB221), GB223, Rituximab (GB241) and other products, covering disease fields such as breast cancer, lung cancer, gastrointestinal tumors, and blood tumors. The Company mainly conducts its businesses in the domestic market.